Low protection from breakthrough SARS-CoV-2 infection and mild disease course in ocrelizumab-treated patients with multiple sclerosis after three mRNA vaccine doses.
Frederik NovakHamza Mahmood BajwaJohn Eugenio CoiaAnna Christine NilssonChristian NielsenDorte K HolmKamilla ØstergaardMathilde Vilhelmine Miller HvidtKeld-Erik BygIsik S JohansenKristen MittlWilliam RowlesScott S ZamvilRiley BoveJoseph J SabatinoTobias SejbaekPublished in: Journal of neurology, neurosurgery, and psychiatry (2023)
The study results demonstrate rates of 59% in breakthrough infections after the third SARS-CoV-2 mRNA vaccination in ocrelizumab-treated patients with MS, without resulting in critical disease courses. These findings suggest the need for continuous development of prophylactic treatments when proved important in the protection of severe breakthrough infection.